Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ELIFEMME vs ALTAVERA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Elifemme is a small-molecule inhibitor of the bromodomain and extraterminal (BET) family of proteins, specifically BRD4. It disrupts the interaction between BET proteins and acetylated histones, thereby inhibiting oncogene transcription including MYC and BCL2.
Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.
Treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an IDH1 mutation,Treatment of adult patients with relapsed or refractory myelodysplastic syndromes (MDS) with an IDH1 mutation
Prevention of pregnancy,Treatment of moderate acne vulgaris (in females ≥15 years with no contraindications)
Subcutaneous injection: 0.5 m L (15 mg) once weekly.
1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.
Terminal elimination half-life is 24-30 hours, allowing once-daily dosing for treatment of relapsed/refractory multiple myeloma.
Levonorgestrel: terminal elimination half-life 25±10 hours; ethinyl estradiol: 13±7 hours. Clinical context: steady-state concentrations achieved within 5-7 days; contraceptive efficacy requires consistent daily dosing.
Primarily metabolized by CYP3A4 and CYP2C8. Minor contribution from CYP2D6.
Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes sulfation and glucuronidation. Desogestrel: rapidly converted to active metabolite etonogestrel via CYP2C9 and CYP2C19; further metabolism by CYP3A4.
Primarily unchanged in feces (approx. 60-70%) via biliary excretion, with renal excretion accounting for <10% of the dose.
Renal excretion of metabolites and unchanged drug: ~30% (levonorgestrel) and ~20% (ethinyl estradiol) in urine; biliary/fecal elimination: ~40-50% as conjugates and metabolites.
>99% bound, primarily to albumin and alpha-1-acid glycoprotein.
Levonorgestrel: 98-99% bound to sex hormone-binding globulin (SHBG) and albumin; ethinyl estradiol: 98% bound to albumin.
Vd/F is 20-30 L (approx. 0.3-0.5 L/kg), indicating extensive tissue distribution.
Levonorgestrel: Vd ~1.8 L/kg (suggesting extensive tissue distribution). Ethinyl estradiol: Vd ~2.4 L/kg.
Approximately 50% (range 30-80%) following oral administration; food decreases AUC by 30% and Cmax by 50%, but no dose adjustment required.
Oral bioavailability: levonorgestrel ~100% (nearly complete); ethinyl estradiol ~45-50% (first-pass hepatic metabolism).
No dose adjustment required for mild to moderate renal impairment (e GFR ≥30 m L/min/1.73 m²). Not studied in severe renal impairment (e GFR <30 m L/min/1.73 m²) or dialysis.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal disease or acute renal failure due to potential fluid retention.
No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate to severe hepatic impairment (Child-Pugh B or C).
Contraindicated in severe hepatic dysfunction (Child-Pugh class B or C). Use caution in mild to moderate impairment (Child-Pugh A); monitor liver enzymes.
Safety and efficacy not established in pediatric patients (<18 years).
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults (1 tablet daily, 21/7 regimen) after evaluation of risks.
No dose adjustment required; however, caution is advised due to potentially decreased renal function. Monitor renal function in elderly patients.
Not indicated for postmenopausal women. No specific geriatric dosing; consider increased risk of thromboembolism, cardiovascular disease, and metabolic effects in older women of reproductive age.
WARNING: QTc PROLONGATION AND RISK OF TORSADE DE POINTES Elifemme causes concentration-dependent QTc interval prolongation. Avoid use in patients with baseline QTc > 470 msec or with factors predisposing to prolonged QTc. Monitor ECG before initiation, after each dose escalation, and periodically during treatment. Correct electrolyte abnormalities before starting therapy.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age (especially >35 years) and with number of cigarettes smoked. Women who use combined hormonal contraceptives should be strongly advised not to smoke.
QTc Prolongation: Monitor ECG and electrolytes; dose reduction or discontinuation recommended if QTc > 500 msec.,Hepatotoxicity: Elevations of ALT/AST and bilirubin reported. Monitor liver function tests every 2 weeks for the first 3 months, then monthly.,Embryofetal Toxicity: Can cause fetal harm. Advise effective contraception in females of reproductive potential during treatment and for 1 month after last dose.,Neutropenia: Grade 3-4 neutropenia may occur. Monitor complete blood counts frequently.,Tumor Lysis Syndrome: Risk in patients with high tumor burden. Ensure adequate hydration and monitor uric acid.
Thrombotic disorders: risk of venous thromboembolism (VTE), stroke, myocardial infarction; discontinue if thrombotic event occurs.,Hepatic disease: discontinue if jaundice or liver function abnormalities develop.,Hypertension: monitor blood pressure; discontinue if uncontrolled.,Carbohydrate metabolism: may affect glucose tolerance; monitor diabetic patients.,Depression: discontinue if significant depression occurs.,Gallbladder disease: increased risk of cholelithiasis.
Concomitant use with strong CYP3A4 inducers,Baseline QTc interval > 470 msec,History of torsade de pointes or congenital long QT syndrome,Hypersensitivity to elseifemme or any excipients
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Estrogen-dependent neoplasia (known or suspected),Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma (known or suspected),Pregnancy (known or suspected),Hypersensitivity to any component
No specific food interactions. ELIFEMME may cause nausea, diarrhea, or constipation; avoid high-fat meals immediately after injection to minimize gastrointestinal side effects. Maintain a balanced diet as part of a weight management program; no known food restrictions.
No significant food interactions. Alcohol does not affect efficacy but may increase risk of adverse effects such as nausea. Grapefruit juice has no known interaction. Avoid excessive alcohol consumption due to potential hepatotoxicity.
ELIFEMME (efavirenz) is contraindicated in the first trimester due to significant teratogenic risk (neural tube defects, anencephaly, microphthalmia). In animal studies, teratogenicity occurred at doses similar to human exposure. Second and third trimester exposure is associated with continued fetal risk, though lower than first trimester. Use only if no alternative and maternal benefit outweighs risk.
ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular defects (relative risk 1.2-1.4) and no consistent increase in other major malformations. Second and third trimesters: No known teratogenic effects, but theoretical risks from estrogenic effects (e.g., feminization of male fetus). Postnatal: No increased risk of long-term developmental effects from pregnancy exposure.
Efavirenz is excreted into human breast milk with a milk-to-plasma (M/P) ratio of approximately 0.5-1.0. Theoretical risk of infant toxicity includes CNS effects (dizziness, drowsiness) and potential long-term neurodevelopmental concerns. HIV-infected mothers should avoid breastfeeding to prevent HIV transmission; in non-HIV scenarios, weigh risks vs benefits.
Combined oral contraceptives may reduce milk production and quality, especially in early lactation. Ethinyl estradiol transfers into breast milk at low levels (M/P ratio approximately 0.1-0.2), excluding clinical effects in term infants. Levonorgestrel transfer is minimal (M/P ratio ~0.2-0.4). Use is generally avoided in breastfeeding women, especially during the first 6 weeks postpartum. Progestin-only methods are preferred.
Pregnancy can decrease efavirenz plasma concentrations by 20-30% due to increased volume of distribution and metabolic clearance. Standard adult dose (600 mg daily) is recommended throughout pregnancy; however, therapeutic drug monitoring is advised, especially in third trimester, with dose increase to 800 mg daily if trough concentrations fall below 1.0 mcg/m L. Postpartum, monitor concentrations to avoid toxicity as clearance normalizes.
Contraindicated in pregnancy. No dose adjustment recommended because use is discontinued upon confirmed or suspected pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased hepatic clearance, altered binding proteins) are not relevant for this indication.
ELIFEMME is a methionine aminopeptidase 2 (Met AP2) inhibitor indicated for the treatment of obesity. Initiate at 2.5 mg subcutaneously once weekly for 4 weeks, then increase to 5 mg once weekly. Monitor for hypersensitivity reactions and injection site reactions. Contraindicated in pregnancy; verify negative pregnancy test before initiation. Avoid concurrent use with other weight loss drugs due to lack of safety data. Assess for depression or suicidal ideation during therapy as mood changes have been reported.
ALTAVERA is a combined oral contraceptive (COC) containing ethinylestradiol and levonorgestrel. It inhibits ovulation via suppression of gonadotropins. Counsel patients to take at the same time daily to maintain efficacy. Missed pill management: if missed within 12 hours, take immediately; if >12 hours, take last missed pill and use backup contraception for 7 days. Be aware of increased VTE risk, especially in smokers over 35. May reduce effectiveness of lamotrigine; monitor seizure control. Initiate on the first day of menses or first Sunday after onset.
Use exactly as prescribed; do not change dose or frequency without consulting your healthcare provider.,Inject subcutaneously in the abdomen, thigh, or upper arm on the same day each week.,Rotate injection sites to reduce risk of injection site reactions.,Seek immediate medical attention if you experience signs of allergic reaction (rash, itching, swelling, difficulty breathing).,Use effective contraception during treatment and for at least 2 months after the last dose; notify your doctor immediately if you become pregnant.,Report any new or worsening depression, suicidal thoughts, or mood changes to your healthcare provider.,Do not share your pen or needles with others, even if they have the same condition.,Store unused pens in the refrigerator; do not freeze. Once opened, store at room temperature (up to 30°C) for up to 30 days.
Take one tablet daily at the same time each day, with or without food.,If you miss a pill by less than 12 hours, take it as soon as you remember. If more than 12 hours, take the missed pill and use a backup method (e.g., condoms) for the next 7 days.,Smoking increases your risk of serious cardiovascular side effects, especially if you are over 35 years old. Do not smoke while taking this medication.,Seek immediate medical attention if you experience sudden severe headache, chest pain, leg pain/swelling, or vision changes (symptoms of blood clots).,This medication does not protect against HIV or other sexually transmitted infections.,If you are taking lamotrigine or other anticonvulsants, tell your doctor; your seizure medication may be less effective.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ELIFEMME vs ALTAVERA, answered by our medical review team.
ELIFEMME is a Oral Contraceptive that works by Elifemme is a small-molecule inhibitor of the bromodomain and extraterminal (BET) family of proteins, specifically BRD4. It disrupts the interaction between BET proteins and acetylated histones, thereby inhibiting oncogene transcription including MYC and BCL2.. ALTAVERA is a Combined Oral Contraceptive that works by Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ELIFEMME and ALTAVERA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ELIFEMME is: Subcutaneous injection: 0.5 m L (15 mg) once weekly.. The standard adult dose of ALTAVERA is: 1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ELIFEMME and ALTAVERA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ELIFEMME is classified as Category C. ELIFEMME (efavirenz) is contraindicated in the first trimester due to significant teratogenic risk (neural tube defects, anencephaly, microphthalmia). In animal studies, teratogeni. ALTAVERA is classified as Category C. ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular def. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.